Lonza plans to invest approximately CHF 500 million to upgrade the facility
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
The institution will be spread over an area of more than 8 acres
Acquisition of exclusive commercialization rights for European markets
Subscribe To Our Newsletter & Stay Updated